Virginia Beach, VA
Ketamine Therapy clinics in Virginia Beach
Virginia Beach has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Virginia permits ketamine under DEA registration; Spravato REMS clinics operate across the state. Most Virginia Beach clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Virginia Beach only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Virginia Beach, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Virginia Beach sits in the affordable range: single IV infusions run 400 to 700 dollars, a full 6 session protocol lands at 2,400 to 4,200, and Spravato copays depend on insurance coverage. A reputable Virginia Beach ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Regulatory context
A note on Virginia's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
HB 898 / Psilocybin Advisory Board (2022, vetoed)
Would have created a state advisory board on psilocybin therapy; vetoed by Governor Youngkin. -
Virginia Drug Control Act
Mirrors federal scheduling.
Virginia enforces federal scheduling. The Virginia Board of Medicine oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Virginia PMP requires controlled substance reporting. Governor Youngkin has vetoed psychedelic-related legislation, signaling a restrictive executive stance.